| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2402694 | Vaccine | 2013 | 4 Pages |
BackgroundHepatitis A is mostly a self-limiting disease but causes substantial economic burden. Consequently, United States Advisory Committee for Immunization Practices recommends inactivated hepatitis A vaccination for all children beginning at age 1 year and for high risk adults. The hepatitis A vaccine is highly effective but the duration of protection is unknown.MethodsWe examined the proportion of children with protective hepatitis A antibody levels (anti-HAV ≥20 mIU/mL) as well as the geometric mean concentration (GMC) of anti-HAV in a cross sectional convenience sample of individuals aged 12–24 years, who had been vaccinated with a two-dose schedule in childhood, with the initial dose at least 5 years ago. We compared a subset of data from persons vaccinated with two-doses (720 EL.U.) at age 3–6 years with a demographically similar prospective cohort that received a three-dose (360 EL.U.) schedule and have been followed for 17 years.ResultsNo significant differences were observed when comparing GMC between the two cohorts at 10 (P = 0.467), 12 (P = 0.496), and 14 (P = 0.175) years post-immunization. For the three-dose cohort, protective antibody levels remain for 17 years and have leveled-off over the past 7 years.ConclusionThe two- and three-dose schedules provide similar protection >14 years after vaccination, indicating a booster dose is not needed at this time. Plateauing anti-HAV GMC levels suggest protective antibody levels may persist long-term.
► Hepatitis A (HepA) causes large economic burden and is vaccine preventable. ► HepA vaccine was 3- and is now a 2-dose schedule; antibody duration is unknown. ► No differences were observed in antibody levels between 3- and 2-dose schedules. ► Booster dose is not needed at this time, 14 years after initial immunization. ► Plateauing antibody levels suggest longer protection will occur.
